Status:
COMPLETED
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
Lead Sponsor:
Uppsala University
Conditions:
Autoimmune Encephalitis
Paraneoplastic Neurological Syndrome
Eligibility:
All Genders
Brief Summary
Autoimmune encephalitis and paraneoplastic neurological syndromes are rare diseases caused by an abnormal immune response toward the nervous system. This can lead to life-threatening symptoms, but is ...
Detailed Description
Methods: 1. Identification of extended cohort: The extended cohort consists of all patients in Sweden tested for any neuronal antibody in serum or CSF between 2015 and 2019. Patients will be iden...
Eligibility Criteria
Inclusion
- Applicable only on Core Cohort:
- All ages, both sexes.
- Neuronal antibody (AMPA 1, AMPA 2, Amphiphysin, CARP VIII, CASPR2, CV2/CRMP5, DPPX, GABA B, GAD65(\>2000 IU/ml by ELISA in serum, or detected in CSF), glycine receptor, Homer 3, Hu, IgLON5, ITPR1, LGI-1, Ma2/Ta, NMDAR, PCA-2, Tr, Ri, SOX1, VGCC, Yo, Zic4), detected in serum or cerebrospinal fluid between 2015-2019
- Antibody test was requested by a health care facility in the Uppsala-Örebro health care region
- Signed informed consent. If the participant is deceased consent will be presumed
Exclusion
- Incomplete personal data or social security number making it impossible to identify and/or contact the patient to get written consent
- Informed consent not signed. If the participant is deceased consent will be presumed
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2022
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04708626
Start Date
October 1 2019
End Date
August 1 2022
Last Update
November 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uppsala University
Uppsala, Uppland, Sweden, 75237